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Abstract. The mechanism(s) leading to widespread hy- 
per-phosphorylation of proteins in Alzheimer's disease 
(AD) are unknown. We have characterized seven new 
monoclonal antibodies recognizing independent phos- 
pho-epitopes in the paired helical filament proteins 
(PHF) found in AD brain. These antibodies show pro- 
nounced immunoreactivity with cultured human neuro- 
blastoma cells that are in the M phase of cell division, 
but have no discernible reactivity with interphase cells. 
Immunoreactivity with these antibodies does not local- 
ize to the microtubule spindles or chromosomes in M 
phase, but is confined to the surrounding cytoplasm. 
Similar staining in M phase is observed with cultured 
cells of various tissue types and species. Cells arrested 
in M phase with the microtubule depolymerizing agent, 
nocodazole, show marked increases in immunoreactiv- 
ity with the antibodies by immunofluorescence staining, 
ELISA, and immunoblotting. In neuroblastoma cells, 
the appearance of the TG/MC phospho-epitopes coin- 
cides with activation of mitotic protein kinases, but not 
with the activity of the neuronal specific cyclin-depen- 
dent kinase, cdk5. These data suggest that the TG/MC 
epitopes are conserved mitotic phospho-epitopes pro- 
duced as a result of increased mitotic kinase activity. To 
investigate this possibility in AD, we examined the 
staining of human brain tissue with MPM-2, a marker 
antibody for mitotic phospho-epitopes. It was found 
that MPM-2 reacts strongly with neurofibrillary tangles, 
neuritic processes, and neurons in AD but has no stain- 
ing in normal human brain. Our data suggest that accu- 
mulation of phospho-epitopes in AD may result from 
activation of mitotic posttranslational mechanisms 
which do not normally operate in mature neurons of 
brain. 
M 
uch evidence (Grundke-Iqbal et al., 1986; Wood 
et  al.,  1986; Lee  et  al.,  1991; Goedert  et  al., 
1992a; Kanemaru et al., 1992) has indicated that 
the PHF found in neurofibrillary tangles (NFT)  1 and neu- 
rites in Alzheimer's disease (AD) brain are composed pre- 
dominantly of hyperphosphorylated tan proteins. Whereas 
normal tau has 3 moles of phosphate per mole of protein, 
paired helical filament proteins  (PHF) have 11  moles of 
phosphate  per  mole  of protein  (Ksiezak-Reding et  al., 
1994).  Aberrant  protein  phosphorylation  has  therefore 
been hypothesized to be a critical step in the formation of 
PHF in AD. Thus, a considerable amount of research has 
focused on the identification of protein kinases responsi- 
ble for excessive phosphorylation in the disease. 
In vitro studies have shown that virtually every serine- 
threonine  protein  kinase phosphorylates tau,  producing 
some characteristic of PHF (Hoshi et al., 1987; Baudier 
and Cole, 1987; Litersky and Johnson, 1992; Steiner et al., 
1990; Mandelkow et al., 1992; Ishiguro et al.,  1992). The 
mapping of several PHF phospho-epitopes to serine/thre- 
1. Abbreviations used in this paper: AD, Alzheimer's disease; APP, amy- 
loid precursor protein; NFT, neurofibrillary tangles; PHF, paired helical 
flament proteins. 
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onine-proline  motifs  in  the  normal  tau  sequence  (re- 
viewed by Kosik and Greenberg, 1994) has directed atten- 
tion to the interaction of various members of the proline- 
directed protein kinase family and tau. The results indicate 
that nearly all members of this kinase family which include 
the ERK/MAP kinases (Drewes et al., 1992; Ledesma et 
al., 1992; Goedert et al., 1992b; Lu et al., 1993), the cdc2 ki- 
nase (Hall et al., 1990; Mawal-Dewan et al., 1992),  cdk2 
(Bauman et al., 1993), cdk5 (Paudel et al.,  1993; Ishiguro 
et  al.,  1994),  and the  glycogen synthase kinase-3  (Man- 
delkow et al.,  1992), phosphorylate recombinant tau pro- 
ducing PHF epitopes. Although in vitro phosphorylation 
of a protein by a given kinase is an important criteria for 
establishing an in vivo kinase-substrate relationship, the 
promiscuity of proline-directed kinases in vitro makes it 
difficult to correlate in vitro activities with physiological 
relevance (Hall and Vulliet, 1991; Nigg, 1993). What would 
substantially assist in the clarification of these in vitro data 
is a cellular model system in which PHF epitopes are ex- 
pressed,  so  that mechanisms leading to  their formation 
may be more clearly defined. 
In the present study we have characterized monoclonal 
antibodies raised against and specific for PHF from AD 
brain in a  model system of human neuroblastoma cells. 
We have found that the phospho-epitopes recognized by 
seven new anti-PHF monoclonal antibodies are expressed 
in a cell cycle-regulated fashion in cultured cells of a vari- 
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elevated in M  phase, and are not detectable in any other 
phases of the cell cycle. We have therefore hypothesized 
that mitotic protein kinases are involved in the production 
of PHF phospho-epitopes. 
Materials and Methods 
Purification of PHF 
PHF were purified from AD brain supernatant using a column of immobi- 
lized Alz-50 antibody as previously described (Vincent et al., 1992). 
Antibodies 
The TG and MC monoclonal antibodies were raised in mice immunized 
with immunoaffinity purified PHF preparations from AD brain. Alz-50 
was produced using basal forebrain homogenates from AD brain as im- 
munogen (Wolozin et al., 1986),  and PHF-1 was made against detergent- 
extracted PHF (Greenberg et al., 1992).  All the above hybridomas were 
grown to yield titers of ~10 0`g antibody per ml culture supernatant. A 
polyclonal antibody recognizing residues 264-288 of the COOH terminus 
of mouse cdc2, an anti-PSTAIR monoclonal antibody, a polyclonal anti- 
body recognizing the COOH-terminal residues .268--283 in human cdkS, 
and the MPM-2 monoclonal antibody were purchased from Upstate Bio- 
technology Inc. (Lake Placid, NY). A  mouse monoclonal antibody spe- 
cific for cdk5 was obtained from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA). Monoclonal antibody against 13-tubulin (IgG2a) was obtained 
from Boehringer-Mannheim Biochemicals (Indianapolis, IN). All isotype- 
specific secondary antibodies were purchased from Southern Biotechnol- 
ogy Assoc. (Birmingham, AL). FITC- and rhodamine-conjugated subtype 
specific antibodies were also obtained from Southern Biotechnology As- 
soc. and Cy5-conjugated mouse IgG secondary antibody for triple labeling 
experiments was  bought  from  Jackson  ImmunoResearch Labs.  (West 
Grove, PA). 
Immunocytochemistry with Human Brain Tissue 
All the cases used in this study were evaluated by neuropathological ex- 
amination of postmortem brain specimens that were immersion fixed in 
10% formalin. Those cases that were clinically diagnosed with senile de- 
mentia of the Alzheimer type were confirmed histopathologically accord- 
ing to the distribution and number of plaques and tangles observed with 
thioflavin S fluorescence staining and with the monoclonal antibody, Alz-50. 
Age matched normal cases had no clinical history of dementia, and no 
thioflavin S or Alz-50 positive lesions, except where indicated. For immu- 
nocytochemical studies, fixed tissue was sectioned with a vibratome at a 
thickness of 50 ~,m, and immunocytochemistry was performed on free- 
floating sections after blocking endogenous peroxidase with 3% hydrogen 
peroxide and nonspecific antibody binding with 5% nonfat milk. All pri- 
mary antibodies were used at dilutions of 1:10 in the 5% milk blocking so- 
lution. The MPM-2 antibody was used at a  1:250  dilution. The specific 
binding of primary antibodies was detected using HRP-labeled goat anti- 
mouse isotype-specific secondary antibodies at dilutions of 1:500 in block- 
ing solution, and diaminobenzidine (Sigma Chemical Co., St. Louis, MO) 
as the chromogen. 
Cell Culture 
The human neuroblastoma line (MSN) was cultured in RPMI medium 
containing 10% fetal bovine serum, as described in Vincent et al. (1994). 
All other cell lines were maintained in DME, supplemented with 10% fe- 
tal bovine serum. Hela cells were kindly provided by Ruchira Das Gupta 
and Howard Sirotkin (Albert Einstein College of Medicine, Bronx, NY). 
For arresting cells in metaphase, exponentially growing cells were treated 
overnight with 10 0`M nocodazole (Sigma Chemical Co.) in 10% DMSO. 
The final concentration of DMSO in the cultures was less than 0.1%. The 
mitotic index of the cultures was determined by propidium iodide staining 
of formalin-fixed cells. In general, ~15% of the cells in asynchronous cul- 
tures were mitotic, whereas ~85% of the cells displayed condensed chro- 
mosomes after nocodazole treatment. 
Immunofluorescence and Confocal Microscopy 
Cells cultured on glass coverslips (Bellco Glass, Inc., Vineland, NJ) were 
fixed with 10% formalin for 40 min at 4°C. Cells were permeabilized using 
two 5 min washes in TBS containing 0.25% Triton X-100. Nonspecific an- 
tibody binding was blocked with 5% milk in TBS and incubations with pri- 
mary antibody were carried out overnight at 4°C. Bound antibody was vi- 
sualized by incubation with FITC-conjugated isotype-specific secondary 
antibodies for 1 h. Interphase nuclei and condensed chromosomes were 
distinguished by double staining with propidium iodide (Sigma Chemical 
Co.). In triple labeling studies, Cy5-conjugated IgG secondary antibody 
was used for visualization of anti-tubulin antibody binding. After sequen- 
tial dehydration with alcohols, the coverslips were mounted in Gurr fluo- 
romount (Bio/medical Specialties, Santa Monica, CA).  Immunofluores- 
cence  data  was  analyzed  using the  Bio-Rad  MRC  600  laser  scanning 
confocal microscope fitted with Nikon Diaphot optics. 
Alkaline Phosphatase Treatment of PHF Preparations 
PHF preparations were prepared by immunoaffinity chromatography as 
described in Vincent and Davies, (1992). Aliquots were incubated with 15 
U/ml of Escherichia  coil alkaline phosphatase (type IIIN; Sigma Chemical 
Co.), for 1 h at 65°C. Samples were boiled with SDS sample buffer before 
electrophoreses in SDS-polyacrylamide gels and transfer to  nitrocellu- 
lose. 
Preparation of Cultured Cell Lysates  for 
Immunoblot Analysis 
MSN ceils were harvested by mechanical shaking and centrifugation. Cell 
pellets were resuspended in Lysis buffer (TBS containing 2 mM PMSF, 2 
mM EGTA, 25 0`M leupeptin, 5 mM NaF, 0.5% Triton X-100, and 0.2% 
SDS), and frozen at -70°C. Lysates were obtained by thawing frozen cell 
suspensions and centrifuging for 2 rain. The resulting supernatants were 
diluted 1:10 with water to reduce the Triton X-100 concentration to 0.05% 
and protein was assayed using the micro Bio-Rad procedure (Bio-Rad 
Laboratories, Richmond, CA). Aliquots of equivalent protein were boiled 
with SDS-PAGE sample buffer and used for electrophoresis and direct 
immunoblotting experiments. In general, 50 0`g protein were loaded per 
lane of a  10% mini gel. Electrophoresis and immunoblotting were per- 
formed as previously described (Vincent et al.,  1994),  except that with 
some antibodies (where indicated) binding was detected using the highly 
sensitive enhanced  chemiluminescence reagent,  i.e.,  ECL  (Amersham 
Corp., Arlington Heights, IL). 
ELISA 
Whole cell  lysates were  assayed by ELISA  and were  prepared  as  de- 
scribed above except without detergents. Lysates were titered into 96-well 
microtiter plates (Nunc, Roskilde, Denmark) starting with 30 0`g protein 
in the first well. Dilutions were made in water. Antigen was bound to the 
plate by drying the samples under a current of air at 37°C for 1 h. Anti- 
body binding was detected with isotype-specific secondary antibodies and 
ABTS substrate solution (Bio-Rad Laboratories). OD was determined us- 
ing  an  SLT  SPECTRA  scanner  (Tecan  Technicals  US  Incorporated, 
Durham, NC), and the data were analyzed by totaling the OD from the 
entire titration as an estimate of the area under the curve. 
Immunoprecipitation 
MSN supernatants generated from cell lysates in the presence of deter- 
gents (see above) were used for immunoprecipitation. Supernatants con- 
taining 100 0`g protein were incubated with 2-3 ~,g of the respective rabbit 
primary antibody for 2-3 h at room temperature. 50 0`1 of a 30% slurry of 
Sepharose beads coupled to protein A (Sigma Chemical Co.) were used to 
bring down the antibody-antigen immune complex. The immunoprecipi- 
tates were washed three times with lysis buffer, reconstituted to the origi- 
nal volume with lx sample buffer and boiled for 3 min. The proteins re- 
leased from the beads were  resolved by SDS-PAGE  and  analyzed by 
immunoblotting. 
For precipitation of mitotic kinase activity with pl3sucl-beads aliquots 
of the supernatants were diluted 1:10 with water to decrease the detergent 
concentration below 0.1%, prior to assay of protein concentration by the 
micro  Bio-Rad  procedure  (Bio-Rad  Laboratories).  100  0`g protein  of 
MSN supernatant were used for the precipitation of pl3-bound mitotic ki- 
nases. 5p,1 of pl3sucl-bound to  agarose beads (Upstate  Biotechnology 
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mixture was centrifuged for 2 min to isolate the beads, and the beads were 
washed with 15 vol of lysis buffer twice, and then twice with 25 vol TBS to 
reduce the concentration of detergent for the kinase assay. 
Histone HI Kinase Assays 
Kinase assays were conducted according to the procedure recommended 
by Upstate  Biotechnology Inc.  The p13-bound proteins were  reconsti- 
tuted to 20 p,1 with TBS. 3-5 Ixl of the slurry were incubated with 5-8 t~g of 
histone H1  (Boehringer Mannheim Biochemicals), and 0.25 mCi ~_32p_ 
ATP (Amersham Corp.) in a final volume of 30 p~l kinase buffer contain- 
ing 50 mM Tris-HCl, pH 7.4, 10 mM MgCI2, 2 mM EGTA, 1 mM DTT, 
2  I~M ATP, and 0.5 ~g/ml protein kinase A  inhibitor (Sigma Chemical 
Co.). The reaction was allowed to proceed for 30 rain at room tempera- 
ture, and stopped with sample buffer and boiling. Samples were loaded 
onto SDS gels for Coomassie blue staining and autoradiography. The in- 
corporation  of labeled phosphate into the histone bands in the gel was 
quantitated using a phosphoimager (Molecular Dynamics, Sunnyvale, CA). 
Results 
The TG and MC Monoclonal Antibodies React with 
Phosphorylated Epitopes in PHF 
The TG and MC monoclonal antibodies were raised against 
PHF purified by affinity chromatography using a column 
of immobilized Alz-50 antibody. This purification proce- 
dure (Vincent and Davies, 1992) does not use any harsh 
detergents which are typically used in conventional PHF 
purification  schemes.  Our  method  thereby  enriches  for 
PHF in their native form and allows for studies of other 
proteins  in  physiological  association  with  the  filaments. 
That the TG/MC antibodies are bona fide markers for AD 
pathology is illustrated by their reactivity with the immu- 
noaffinity purified PHF preparation on immunoblots (Fig. 1). 
All the antibodies react with the principal 57-68-kD trip- 
let PHF proteins, and also with :aggregation and degrada- 
tion products of the triplet proteins. Thus, the pattern of 
immunoreactivity of the TG and MC antibodies with PHF 
resembles the pattern of immunoreactivity with the estab- 
lished  PHF  antibodies,  PHF-1  (Greenberg et  al.,  1992), 
and  Alz-50 (Wolozin et al.,  1986;  Ksiezak-Reding et al., 
1988).  Immunoreactivity with  all  of the  antibodies  and 
PHF is eliminated or greatly reduced following treatment 
of the  PHF preparation  with  alkaline  phosphatase  (Fig. 
1, ÷). This is direct evidence that these antibodies are di- 
rected against phosphorylated epitopes in PHF, an  idea 
supported by the observation that none of the antibodies 
react with normal tau (data not shown). As is usually ob- 
served with Alz-50 immunoreactivity, an increase in elec- 
trophoretic mobility is observed after phosphatase  treat- 
ment but the intensity of immunoreactivity is unaffected 
(Fig. 1, Alz-50 lanes). These results also verify the specific- 
ity of the  alkaline  phosphatase ,  and  control for the  ab- 
sence of PHF degradation during the phosphatase incuba- 
tion. 
The TG/MC Antibodies Are Markers for AD Pathology 
and React with Cultured Cells in Mitosis 
Immunocytochemical analyses  with  the  PHF  antibodies 
were conducted using routine formalin-fixed autopsy tis- 
sue  from  histopathologically  confirmed  AD  and  age- 
matched  normal  cases.  The  observations  are  based  on 
studies of 16 AD and 16 age-matched normals, except for 
Figure  1.  Effects of alkaline phosphatase treatment on the immu- 
noreactivity with the TG/MC antibodies and purified PHF. Sam- 
ples of the native immuno-affinity purified PHF preparation (-) 
and preparations  incubated with alkaline phosphatase  (AP) (+) 
were loaded at equivalent amounts of protein into SDS gels. Af- 
ter electrophoreses and electrophoretic blotting, nitrocellulose strips 
were  stained  with  the indicated  PHF antibodies.  The staining 
with TG-4, MC2, MC15, PHF-1, and Alz-50 was visualized colori- 
metrically, and the remainder were detected by ECL (exposure 
time 30 s). Pretreatment of PHF preparations  with alkaline phos- 
phatase decreased TG/MC immunoreactivity with PHF, suggest- 
ing that the antibodies react with phosphorylated epitopes in PHF. 
TG-3, which has been used to examine tissue from more 
than 60 cases, and Alz-50 and PHF-1 which have been very 
extensively used for studies of AD. The antibodies were 
also used in indirect immunofluorescence staining of hu- 
man neuroblastoma cells (MSN), and the fluorescence was 
analyzed by dual confocal laser microscopy (Fig. 2). 
Like the previously characterized antibodies, Alz-50 and 
PHF-1, all the TG and MC antibodies discriminate strongly 
between normal and AD brain. In normal brain, there is 
either no staining (TG-3, MC3, and MC5), some faint pro- 
cess and occasional cellular staining (TG-4, MC6, MC15), 
or staining of cellular nuclei (MC2). In AD brain, all the 
antibodies react intensely with the classical neurofibrillary 
lesions, namely, NFT, the neuritic elements of senile plaques, 
and the neuropil threads (Fig. 2). 
When applied to the MSN neuroblastoma cells the TG/ 
MC  antibodies  show pronounced reactivity with cells in 
mitosis (Fig. 2), but very little to no reactivity with inter- 
phase cells. Cells in mitosis were distinguished from inter- 
phase cells by the pattern of chromosomal staining with 
propidium iodide, a dye that displays intense fluorescence 
of condensed chromosomes but a  more pale  and diffuse 
staining of interphase nuclei. Unlike the antibodies recog- 
nizing  phospho-epitopes,  staining  with  the  sequence  di- 
rected antibody Alz-50 is  uniformly distributed through- 
out the cytoplasm of all cells, with no increase in mitotic 
cells. 
The TG/MC Antigens Do Not Colocalize with the 
Microtubule Spindle Apparatus or Chromosomes in 
Mitotic Cells 
Progression through mitosis can be monitored by the dy- 
namic phase-specific changes in the microtubular network 
visualized with anti-tubulin antibodies. We explored this 
means for defining the precise temporal and spatial distri- 
bution of TG and MC immunofluorescence in mitotic MSN 
cells. Double immunofluorescence staining with the TG/ 
MC  antibodies  and  an  anti-13-tubulin  antibody  showed 
that  TG/MC  immunofluorescence is  most  prominent  in 
mitotic metaphase (Fig. 3 A, shown for 13-tubulin [red] and 
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TG/MC antibodies. Formalin-fixed  tissue sections from the hippocampus of normal and AD cases were stained with the indicated anti- 
bodies. Light micrographs were generated using Nomarski optics to indicate the presence of tissue in those panels with negative stain- 
ing. The TG/MC antibodies stain neurofibrillary lesions in AD brain tissue (middle), but have little to no reactivity with normal human 
brain (left).  The bar in the light microscopy pictures is 20 ixm. Double immunofluorescence staining was conducted with MSN cells 
grown on glass coverslips, using the TG/MC antibodies (green) and propidium iodide (red) as a counter stain for chromosomal material 
(right). Data were analyzed by dual confocal laser microscopy. The TG/MC antibodies display  immunofluorescence in M phase cells but 
not in interphase cells. The bar in the fluorescence micrographs represents a range of 8--10 txm. 
TG-3  [green]).  Triple fluorescence staining with the TG/ 
MC antibodies, [~-tubulin antibody, and propidium iodide, 
shows localization of TG/MC-immunofluorescence in the 
cytoplasm  surrounding  the  spindle  apparatus,  with  no 
staining of any of the structural components of the mitotic 
microtubule organizing centers,  and  no  staining of chro- 
mosomes  (shown  with  TG-3  [green],  tubulin  [red],  and 
propidium iodide [blue]  Fig. 3 B). In contrast, the pattern 
of immunofluorescence  with  the  PHF-1  antibody in  mi- 
totic cells differs from that of the TG/MC antibodies, both 
Vincent et al. Mitotic Mechanisms in A lzheimer's Disease?  417 Figure  3.  Temporal and spatial distribution of TG/MC imrnunofluorescence in mitotic cells. (A) Double staining of MSN cells in 
metaphase: MSN neuroblastoma cells were subjected to double immunofluorescence staining with the TG-3 antibody and an antibody 
against 13-tubulin. TG-3 staining detected with anti-mouse IgM-FITC (green)  does not colocalize with the staining of the tubulin anti- 
body as visualized with anti-mouse IgG-rhodamine (red).  Only cells in metaphase are stained with TG-3, whereas surrounding inter- 
phase cells are not. (B) Triple staining of MSN cells in metaphase: these cells were stained with TG-3 (green), the tubulin antibody (red) 
and propidium iodide (blue),  to show the lack of colocalization of TG-3 immunofluorescence with the microtubule spindles or the 
metaphase chromosomes. The magnification for this micrograph is 1.6-fold that in A. (C) Hela cells double stained with TG-3 and pro- 
pidium iodide. TG-3 staining (green)  is found only in the mitotic Hela cell (right), but not in the adjacent interphase cell (left).  (D-F) 
Cells were triple stained with the tubulin antibody (shown in D), TG-3 (shown in E), and PHF-1 (shown in F), to illustrate the differ- 
ences in distribution of the TG-3 and PHF-1 antigens in metaphase (cell on upper left of each panel) and in anaphase (cell on lower right 
of each panel). TG-3 staining is localized to a peripheral region of the cytoplasm in both mitotic cells, but the intensity of staining is re- 
duced in anaphase relative to metaphase. In contrast, PHF-1 immunofluorescence is distributed throughout the body of the mitotic cells, 
and is not reduced in anaphase. The magnification for panels D-F is the same as in A. Bars: (A and C) 10 ixm. 
in subcellular distribution and in timing. These differences 
are  best  illustrated  when  cells  are  triple  stained  with 
PHF-1, TG or MC antibody, and 13-tubulin antibody (Fig. 
3,  D-F).  While TG/MC immunofluorescence  is confined 
to the cytoplasm peripheral to the spindle apparatus and 
chromosomes (Fig. 3  E), PHF-1 immunofluorescence oc- 
curs throughout the mitotic cell overlapping with the spin- 
dles  and  chromosomes  (Fig.  3  F).  When  segregation  of 
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rescence with the TG and MC antibodies is greatly dimin- 
ished (Fig. 3 E), whereas PHF-1 immunofluorescence re- 
mains unaltered (F). 
TG/MC Antibodies Are M Phase Specific in Different 
Cell Types and Species 
To rule out the possibility that the mitotic profile of TG/ 
MC  immunofluorescence  is  a  phenomenon  unique  to 
MSN cells, we examined cells of other lineages and species 
for similar  immunoreactivity. Identical  results  were  ob- 
tained  with  HeLa cells,  human  lymphocytes, human  B 
cells, human astrocytes, and mouse and rat fibroblasts. Fig. 
3 C illustrates the specific immunofluorescence with TG-3 
in a Hela cell with condensed chromosomes, and the lack 
of fluorescence associated with a neighboring interphase 
nucleus. These data suggest that the epitopes recognized 
by the TG and MC antibodies belong to a family of con- 
served mitotic antigens. 
Immunoreactivity with the TGIMC Antibodies Is 
Elevated in Nocodazole-arrested Cells 
To establish whether immunoreactivity with the TG/MC 
antibodies is activated specifically in mitosis, we made use 
of nocodazole, a  microtubule depolymerizing agent that 
arrests cells in metaphase. The effects of noeodazole were 
assessed by immunofluorescence (data not shown), ELISA, 
and immunoblotting. Nocodazole treatment produced an 
increase in the total number of cells in metaphase as indi- 
cated by double staining with propidium iodide (Fig. 4). 
Exponentially growing cultures had an average of 15% of 
the cells in M phase and after nocodazole this number rose 
to 85 %. The number of cells stained with the TG/MC anti- 
bodies increased concurrently with the number of cells in 
M phase (Fig. 4). Whole cell lysates from control and no- 
codazole-treated cultures were assayed by ELISA for total 
cellular  immunoreactivity  with  the  TG/MC  antibodies 
(Table I). A  significant increase in immunoreactivity with 
TG-3, TG-4, MC2,  MC3,  MC5,  MC6,  and MC15,  is  ob- 
served with nocodazole-treated cells relative to the con- 
trols. On the other hand, total cellular immunoreactivity 
with PHF-1 and Alz-50 in the ELISA remains unchanged 
(Table I). 
Nocodazole treatment produced an increase in TG and 
MC reactivity with certain antigens on immunoblots (Fig. 
5). In general, marked increases in immunoreactivity with 
one  or  two  specific  antigens  was  seen,  but  phospho- 
epitopes  recognized  by  some  antibodies  appear  more 
ubiquitous. For example, TG-3 recognizes a  105-kD anti- 
gen that is not recognized by any other TG or MC anti- 
body, whereas a  125-kD mitotic antigen is recognized by 
TG-4, MC2, MC15, and MC6, and a 33-35-kD  antigen is 
recognized by MC5 and MC15. 
Surprisingly, none of the TG/MC antibodies react with 
the 55-57-kD  tau proteins which are readily detected with 
Alz-50 and PHF-1 (Fig. 5). We have confirmed these find- 
ings using heat stable fractions in which the tau proteins 
are  characteristically enriched  (data  not  shown).  More- 
over, the reactivity of the  PHF-1  antibody with tan  de- 
creases upon treatment with nocodazole, as does the ap- 
parent  molecular weight  of tan  in  SDS-PAGE  (Fig.  5), 
suggesting  that  tau  becomes  dephosphorylated  under 
these conditions. These results concur with the lack of a 
quantitative increase (or slight decrease) in PHF-1 immu- 
noreactivity in ELISA. On the other hand, the metaphase- 
associated increases in TG and MC immunofluorescence, 
are corroborated by quantitative increases in total cellular 
immunoreactivity with the antibodies in ELISA, and in- 
creased immunoreactivity with specific antigens on immu- 
noblots. 
TGIMC Reactivity in Mitotic Cells 
Correlates with an Increase in Mitotic Kinase Activity 
But Not cdk5 Activity 
The progression of mitotic cell division is driven by a cas- 
cade of protein phosphorylation mediated by the cdc2 ki- 
nase/cyclin B complex whose activity peaks in metaphase 
(reviewed by Nurse, 1990; Mallet,  1991).  While the level 
and activity of cdc2 in dividing cells is high, the kinase is 
barely detectable in fully differentiated cells such as neu- 
rons of adult brain  (Hayes et al.,  1991;  Meyerson et al., 
1992).  Instead, postmitotic neurons have been found to 
contain another cdc2-related cyclin-dependent protein ki- 
nase called cdk5 (Hellmich et al., 1992; Lew et al., 1992; 
Tsai et al., 1993). Although cdk5 is expressed in all tissues, 
it is active only in differentiated neurons (Lew et al., 1994; 
Tsai et al., 1994). The kinase has been reported to phos- 
phorylate tau in vitro producing PHF epitopes (Bauman et 
al., 1992; Hisanaga et al., 1993; Paudel et al., 1993), and is 
therefore a more reasonable candidate for PHF phospho- 
rylation than is the cdc2 kinase. 
Our findings above show abundant expression of PHF 
phospho-epitopes in  cycling mammalian  cells of various 
tissue types, none of which are expected to have any cdk5 
activity. The appearance of the TG/MC phospho-epitopes 
in these cells in metaphase synchronizes with the optimal 
activity of the mitotic cdc2 kinase, and their reduced ap- 
pearance  in  anaphase  coincides with  the  inactivation of 
the cdc2 kinase. We therefore hypothesized that mitotic 
kinases may be responsible for the production of the TG/ 
MC phospho-epitopes. To verify this, we assayed the ac- 
tivities of the mitotic kinase cdc2 and cdk5 in lysates from 
control and nocodazole-treated MSN cells. 
An  antibody recognizing a  COOH-terminal  sequence 
and specific for the p34 cdc2 kinase, and a  cdk5-specific 
polyclonal antibody were used to immunoprecipitate the 
respective  kinases  for  activity  assays.  Reciprocal  cross 
blotting of the cdc2 and cdk5 immunoprecipitates revealed 
no detectable cdk5 immunoreactivity in the cdc2 precipi- 
tate from control or nocodazole-treated cells, and no cdc2 
contamination of the precipitated cdk5 kinase from either 
samples (Fig. 6 A). In addition, mitotic kinase activity was 
precipitated using an agarose conjugate of the yeast pro- 
tein,  pl3sucl,  which  forms  a  stable  functionally  active 
complex with mitotic kinases (Brizuela et al.,  1987; Dra- 
etta et al., 1987). Kinase activities were assayed using his- 
tone H1 as exogenous substrate, and incorporation of la- 
beled phosphate  into the histone  bands  in the gel were 
quantitated using a Phosphoimager. H1 kinase activity was 
increased 10-fold in pl3sucl and 2-fold in cdc2 precipitates 
obtained  from  nocodazole-treated  cells  in  comparison 
with precipitates isolated from control cells (Fig. 6 B). In 
Vincent et al, Mitotic Mechanisms in Alzheimer's Disease ?  419 Figure 4.  Effects of nocodazole on TG-3 immunofluorescence staining in MSN cells. Asynchronous cultures of MSN cells (control) and 
those treated with nocodazole were double stained with TG-3 (green, top panels) and propidium iodide (red). Nocodhzole increased the 
number of cells in M phase, and concomittantly increased the number of cells stained with TG-3. Additional samples were double 
stained with Alz-50 (green, bottom) and propidium iodide (red) and showed no increase in Alz-50 staining accompanying the nocoda- 
zole-induced increase in M phase cells. Data were analyzed by confocal laser microscopy. Bar, 10 p~M. 
contrast,  there  was no detectable  activity in the cdk5 ki- 
nase  precipitates  from  either  control  or  nocodazole- 
treated samples. The failure to detect cdk5 kinase activity 
in these samples is not due to the cdk5 antibody used for 
precipitation,  because the same antibody does precipitate 
active cdk5 kinase from human brain tissue (Fig. 6 A). In- 
stead, the lack of measurable cdk5 kinase activity in these 
neuroblastoma cells is consistent with the data from Tsai 
et al. (1993), showing an absence of cdk5 activity in neuro- 
blastoma cells despite  high cdk5 protein levels.  These ki- 
nase activity assays support the suggestion that the appear- 
ance of the TG and MC epitopes in MSN neuroblastoma 
cells correlates with increased mitotic kinase activity, but 
not with cdk5 activity. 
The Monoclonal Antibody MPM-2, a Marker for 
Mitosis, Reacts with NFT, Senile Plaques, and Neurons 
in AD 
The  correspondence  between  the  appearance  of  PHF 
phospho-epitopes and increased mitotic kinase  activity in 
dividing cells, led to speculation that a  similar increase in 
The Journal of  Cell Biology,  Volume 132, 1996  420 Table L Effects of Nocodazole on the Immunoreactivities of the 
TG/MC Antibodies with MSN Cell Lysates in ELISA 
Antibody  Control  Nocodazole  P value 
mean +- SEM  mean ~ SEM 
TG-3  2.10 ±  0.18  4.24 -  0.11  0.000 
TG-4  1.72 --- 0.31  4.25 ± 0.28  0.003 
MC2  3.83 --+ 0.49  9.36 -  0.90  0.003 
MC3  1.26 --- 0.18  2.47 -+ 0.46  0.022 
MC5  1.38 --- 0.19  1.93 --- 0.52  0.107 
MC6  1.89 ± 0.28  4.93 +- 0.97  0.003 
MC15  4.84 --+ 0.60  10.94 ± 0.49  0.002 
PHF-1  4.00 ± 0.13  3.82 ± 0.23  0.716 
AIz-50  1.69 -  0.19  1.60 ± 0.29  0.576 
Total cell lystates were prepared from control and nocodazole treated MSN cultures, 
and serially  diluted into microtitre  ELISA  plates. Immunoreactivity  with the TG/MC 
antibodies was assayed using isotype-specific  secondary antibodies conjugated with 
HRP and ABTS substrate. The units for activity are arbitrary. The data represent 
means for a total of six determinations in the case of TG-3, TG-4, and PHF-1, and 
three determinations for the remaining antibodies, with standard errors of the mean. 
Differences  between  control  and nocodazole  treated specimens  were  evaluated  using a 
paired t test, and P values are presented for the significance  of the differences.  Total 
cellular immunoreactivity  with the TG/MC antibodies was increased following  treat- 
ment of MSN cells with nocodazole. 
mitotic kinase  activity may be responsible  for production 
of  these  mitotic  phospho-epitopes  in  AD.  If  a  mitotic 
mechanism is involved in AD pathology, then other mark- 
ers for mitosis would be found in AD  brain tissue. We ex- 
amined  the  staining  of  routinely  fixed  autopsy  human 
brain  tissue  with  the  monoclonal  antibody  MPM-2  that 
was  raised  against  mitotic Hela  cells (Davis  et  al.,  1983), 
and recognizes a phospho-epitope  that is highly conserved 
in mitotic proteins of all eukaryotic species (Vandre et al., 
1984,  Vandre et al.,  1986; Keryer et al.,  1987; Engle et al., 
1988; Wordeman  et al., 1989; Tombes et al., 1991; Vandre 
et  al.,  1991).  No  detectable  staining  is observed  with  this 
antibody  in  hippocampal  or  temporal  cortical  brain  sec- 
tions from 12  normal  individuals.  On the other hand,  the 
MPM-2 antibody displays widespread staining of NFT and 
neuritic  plaques  in  hippocampal  and  cortical  tissue  sec- 
tions from 12 AD  cases (Fig. 7 A). In addition to the stain- 
ing  of  these  lesions  in  AD,  the  MPM-2  antibody  reacts 
with  large  numbers  of  hippocampal  pyramidal  cells  dis- 
playing a  punctate pattern  in the cytoplasm.  Similar stain- 
ing of neurons  is not observed in normal  brain  tissue.  To 
verify that the MPM-2 antibody is specific for mitotic cells, 
we stained MSN cultures with the antibody and found that 
Figure 5.  The effects of nocodazole on the immunoreactivity of 
the TGIMC antibodies with MSN proteins in immunoblots. De- 
tergent-extracted supernatants from control (-) and nocodazole- 
treated (+) MSN cell cultures were immunoblotted with the TG/ 
MC antibodies. The staining with MC15 was detected colorimet- 
rically,  and  the  staining  with  the  remaining  antibodies  was  de- 
tected by ECL (exposure time 10-30 s). The TG/MC antibodies 
show marked  increases  in immunoreactivity with proteins  in M 
phase extracts relative to control. 
Figure 6. (A) Reciprocal immunoprecipitation and cross blotting 
with cdc2 and cdk5 antibodies and extracts from control and no- 
codazole-treated MSN cells. Supernatants from control (C) MSN 
cells and those incubated with nocodazole (N) containing equal 
amounts of protein were subjected to immunoprecipitation with 
the COOH-terminal polyclonal cdc2 antibody (left) and an anti- 
cdk5 polyclonal antibody (right) as described in methods. In the 
two upper panels the cdc2 detection antibody is an anti-pstaire 
monoclonal antibody, and in the bottom panels the detection an- 
tibody is an anti-cdk5 monoclonal antibody. The first two lanes 
marked C and N in the left panels represent the starting superna- 
tants from control and nocodazole treated cells respectively. Cp 
and Np refer to the precipitates from control or nocodazole cells, 
and Cs and Ns represent the supernatants  remaining after each 
precipitation. The results indicate that the cdc2-immunoprecipi- 
tate is not contaminated with any co-precipitated cdkS, and that 
the  cdk5  immunoprecipitate  is  free  from  any  co-precipitating 
cdc2. (B) Histone H1 kinase assay with pl3sucl-precipitates, cdc2 
immunoprecipitates,  and cdk5 immunoprecipitates from control 
(C)  and  nocodazole-treated  MSN cells (N).  Supernatants  from 
control and nocodazole-treated cells were incubated with GST- 
pl3sucl-agarose beads to enrich for mitotic kinases. The p13sucl 
precipitates along with aliquots of the cdc2 and cdk5 immunopre- 
cipitates shown in A, were incubated with histone H1 and 3,32p  - 
ATP, and the phosphorylated mixtures were resolved by electro- 
phoreses. The gel was stained with Coomassie blue (left), dried, 
and  subjected  to autoradiography  (right). The relative amounts 
of phosphate  incorporation into the histone bands were quanti- 
tated using phospholmager. The histone Hl-phosphorylating ac- 
tivity  of  cdc2  immunoprecipiated  from  M  phase  extracts  was 
greatly increased relative to the control. On the other hand, cdk5 
immunoprecipitates from M  phase extracts showed no increased 
phosphorylating activity. The last lane labeled Br is a kinase reac- 
tion with cdk5 immunoprecipitate from normal human brain, and 
controls for the ability of the cdk5 polyclonal antibody to precipi- 
tate active cdk5. 
Vincent et al. Mitotic  Mechanisms in Alzheimer's Disease?  421 Figure 7.  (A) Staining of human brain and MSN cells with the MPM-2 mono- 
clonal antibody. Sections of hippocampal tissue from normal and AD cases 
were stained with the MPM-2 antibody. MPM-2 reacts with NFT, neurites of 
senile plaques, and neurons in AD, but has no detectable reactivity in normal 
brain. The bar shown in the light micrographs represents 20 ~m. Double stain- 
ing experiments were conducted with the MSN cells using MPM-2 (green) and 
propidium iodide (red) to show that MPM-2 is specific for cells in M phase. 
Fluorescence data were analyzed by confocal laser microscopy. Bar = 10 Ixm. 
(B) Immunoreactivity of MPM-2 with PHF and MSN lysates. Immunoaffinity 
purified PHF preparations and detergent-extracted supernatants from control 
(-) and nocodazole-treated  (+) MSN cells were subjected to electrophoreses 
and electrophoretic  blotting. For comparison, the same amounts of protein 
were loaded onto this gel as were loaded for studies with the TG/MC antibod- 
ies in Figs. 1 and 5, respectively. The blot was stained with the MPM-2 anti- 
body, and staining was detected by ECL, with an exposure time of 30 s. Al- 
though MPM-2 displayed increased reactivity with M phase MSN cell extracts 
relative to control, no MPM-2 reactivity was detected with the PHF sample af- 
ter exposure with ECL reagent for 15 min. 
it reacted exclusively with cells undergoing mitosis (Fig.  7 
A). On immunoblots MPM-2 showed a dramatic increase 
in immunoreactivity with a number of proteins in nocoda- 
zole-treated cell lysates relative to the control lysates (Fig. 
7).  MPM-2 does not react with the immunoaffinity puri- 
fied PHF preparation, suggesting that it recognizes other 
phosphoproteins in  AD brain that  are  not detectable in 
normal brain. 
Discussion 
The temporal coincidence of the occurrence of phospho- 
epitopes recognized by seven new AD-specific monoclonal 
antibodies with optimal mitotic kinase  activity in cycling 
eukaryotic cells,  has led us to hypothesize that mitotic ki- 
nase activity produces these phospho-epitopes in AD pa- 
thology.  This  hypothesis  is  supported  by  evidence  ob- 
tained with the monoclonal antibody, MPM-2, which was 
raised against mitotic HeLa extracts and shows abundant 
reactivity  with  neurofibrillary  pathological  structures  in 
AD brain tissue, but no reactivity in normal brain. 
The confinement of AD-specific phospho-epitopes to M 
phase of eukaryotic cell division is of value in predicting 
which  protein  kinase  produces  these  epitopes  in  intact 
cells. Evidence suggests that the MAP kinases, GSK-3 ki- 
nase, and the nonmitotic cyelin dependent kinases are not 
activated in M phase, and may be excluded from having a 
role  in  PHF  epitope  formation  in  dividing  cells.  From 
amongst the protein kinases that have been implicated in 
PHF phosphorylation in  vitro,  only the  mitotic kinases, 
p34 cdc2 and cdk2 are activated in M phase, and are there- 
fore likely to be involved in the production of the  PHF 
epitopes. Mitotic kinases have also been implicated in the 
formation of the MPM-2 epitope (Verde et al.,  1990; Ya- 
mashita et al., 1990; Tombes et al., 1991) which is elevated 
in M phase, and in AD brain. 
The suggestion that mitotic kinases may produce mitotic 
phospho-epitopes in brain presents a puzzle, because mi- 
totic kinases are abundant in proliferating neurons but be- 
come undetectable upon terminal  differentiation  (Hayes 
et al.,  1991; Meyerson et al.,  1992; Freeman et al.,  1994). 
However, cdc2 kinase immunoreactivity has been described 
in NFT in AD brain tissue using a spectrum of cdc2-spe- 
cific antibodies (Wood et al.,  1993; Liu et al.,  1995).  The 
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novel PHF-associated  33-kD  kinase  reactive with  NH2- 
and COOH-terminal cdc2 antibodies but lacking reactivity 
with anti-pstaire antibodies. Antibodies directed at COOH- 
terminal cdc2 sequences are  the  only available reagents 
entirely specific for cdc2 (Draetta and Beach, 1988). An 
additional  study  employing  COOH-terminal,  cdc2-anti- 
bodies found elevated levels of p34 cdc2 in extracts from 
AD brain in comparison with normal brain (Ledesma et 
al., 1992). The striking association of the cdc2 kinase with 
NFT in AD brain supports a role for this kinase in the dis- 
ease pathology. It is unclear why the TG/MC and MPM-2 
epitopes, which are present in most M phase cells in cul- 
ture, are totally undetected in nonneuronal proliferating 
glial and endothelial cells in brain. A possible explanation 
is that these epitopes in dividing cells and NFT may be dif- 
ferentially sensitive to the method of fixation of brain tis- 
sue, an idea reminiscent of tau epitopes which are unde- 
tectable in neurons after formalin fixation, but are clearly 
evident in  NFF in  formalin-fixed tissue  from AD  brain 
(reviewed by Kosik and Greenberg, 1994).  An intriguing 
adjunct to the suggested role of mitotic kinases in AD, is 
the  phosphorylation  of  the  amyloid  precursor  protein 
(APP) by cdc2, with maximal phosphorylation at the G2/ 
M phase of the cell cycle (Suzuki et al., 1994). It is believed 
that inappropriate processing of the APP protein in AD 
may be crucial to the massive deposition of insoluble 13-amy- 
loid in the brains of AD patients (Kang et al., 1987; Haas 
et  al.,  1992).  Although  phosphorylation of APP  by the 
cdc2 kinase has not been reported in AD brain tissue, this 
posttranslational  event has  been suggested  to affect the 
proteolytic processing of the APP protein. 
Our finding of the TG/MC phospho-epitopes in HeLa 
cervical carcinoma cells, B and T cells, and fibroblasts, i.e., 
cells without functionally active cdk5 kinase (Lew et al., 
1994; Tsai et al., 1994), suggests that cdk5 may not be es- 
sential for formation of these epitopes. Histone H1 kinase 
assays also demonstrate that cdk5 is not active in nocoda- 
zole-treated neuroblastoma, and is therefore unlikely to 
be involved in the formation of PHF epitopes in M phase. 
While our data illustrate the significance of mitotic kinases 
in AD they do not exclude the possibility that other ki- 
nases like cdk5 may function either concomitantly or in se- 
ries to produce other phospho-epitopes in AD. 
Despite  the  colocalization of the  PHF-1  and  TG/MC 
phospho-epitopes in NFT in AD, it appears that the bio- 
chemical  mechanisms  regulating  the  turnover  of  these 
phospho-epitopes  may  be  different.  While  the  TG/MC 
phospho-epitopes are  quantitatively increased in mitotic 
cells, the PHF-1 epitope in tau becomes dephosphorylated 
during mitosis. This finding is consistent with the increased 
ability of tau to bind to microtubules when it is dephos- 
phorylated  (Lindwall  and  Cole,  1984;  Drechsel  et  al., 
1992). It is however, in contrast to the data of Pope et al. 
(1994) who showed that PHF-1 immunoreactivity with tau 
from mitotic cells is enhanced relative to tau from inter- 
phase ceils. Our studies also indicate that the TG and MC 
antibodies show little reactivity with hyperphosphorylated 
MSN  tau  which  we  previously showed  (Vincent  et  al., 
1994)  to be strongly reactive with  PHF-1, NP8, and the 
T3P antibody of Lee et al. (1991). Since the TG/MC phos- 
pho-epitopes appear to be evolutionarily conserved in mi- 
totic cells, their antigens may correspond to previously de- 
scribed mitotic proteins. Although some of these proteins 
seem similar to the mitotic phosphoproteins recognized by 
the MPM-2 antibody in mitotic MSN cells, MPM-2 does 
not react with our purified PHF preparation on blots, rais- 
ing the possibility that the staining of NFT with MPM-2 
may be associated with yet another independent group of 
antigens. Thus in addition to tau, other as yet unidentified 
aberrantly phosphorylated proteins may be present in AD 
brain.  Further studies  aimed  at the identification of the 
TG/MC and MPM-2 antigens in AD brain would greatly 
clarify this picture. Just as the occurrence of the MPM-2 
epitope in proteins is indicative of mitotic kinase activity 
regardless of what proteins the epitope is found in during 
mitosis,  our  data  point  to  a  functional  relationship  be- 
tween mitotic kinase activity and the formation of the AD- 
specific TG/MC phospho-epitopes. It is not unreasonable 
to expect that misappropriate activation of mitotic kinases 
in  mature  neurons  might  lead  to  production of mitotic 
phospho-epitopes in proteins quite different from those in 
cycling cells, because  the  available protein substrates  in 
mature neurons are quite different. Thus the TG/MC and 
MPM-2 antigens in AD may not necessarily be the same 
antigens found in cultured cells in M  phase. We suggest 
that,  irrespective  of  the  identities  of  the  TG/MC  and 
MPM-2 antigens in AD brain, mitotic kinases appear to be 
the most reasonable candidates for the production of the 
TG/MC and MPM-2 phospho-epitopes. 
Cell cycle proteins are progressively being implicated in 
cellular processes that encompass the entire repertoire of 
cellular responses to external and  internal stimuli  (Wil- 
liams et al., 1992; Williams and Smith, 1993). Programmed 
cell death has recently been hypothesized to result from 
aberrant cell cycle control leading to  "abortive mitosis" 
(Ucker et al., 1991; Lee et al., 1993). Certain studies have 
shown a lack of involvement of the cdc2 kinase in apopto- 
sis  (Norbury et al.,  1994;  Oberhammer et al.,  1994)  and 
others support activation of cdc2 (Steinmann et al., 1991; 
Meikrantz et al., 1994; Shi et al., 1994). Although it is not 
known whether neuronal death in AD proceeds by apop- 
tosis,  necrosis,  or  some  as  yet  unidentified  mechanism 
(Dickson, 1995; Lassman et al., 1995), the cdc2 kinase or 
other mitotic kinases may be a convergent point for any 
one of the mechanisms cited above. Recent reports of the 
occurrence of S phase markers, p105 (Masliah et al., 1993) 
and Ki67 (Smith and Lippa, 1995) in NFT are consistent 
with the idea of misregulated expression of proliferation 
antigens in AD. A  systematic analysis of mitotic kinases 
and  their  associated  proteins  would  help  determine 
whether production of mitotic phospho-epitopes in AD is 
mediated by mitotic posttranslational mechanisms or other 
cellular pathways. 
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